​

CAR T-cell therapy is a topic in the health domain with significant developments in policy, regulation, and public health impact.

Key developments include caribou biosciences halts car-t programs and seeks strategic alternatives after failing to secure funding, three deaths in novartis car t-cell therapy trials for autoimmune disease prompt caution, adicet bio's off-the-shelf car-t therapy shows promise in lupus trial, among other significant events and policy changes.

Source: Geo Health Space